OncoCyte Co. (NASDAQ:OCX) Major Shareholder Buys $3,880,250.05 in Stock

OncoCyte Co. (NASDAQ:OCX) major shareholder Broadwood Partners, L.P. purchased 1,315,339 shares of the stock in a transaction dated Wednesday, October 2nd. The stock was acquired at an average cost of $2.95 per share, for a total transaction of $3,880,250.05. Following the transaction, the insider now owns 6,244,405 shares of the company’s stock, valued at approximately $18,420,994.75. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

OncoCyte Stock Up 1.0 %

OncoCyte stock opened at $3.04 on Wednesday. OncoCyte Co. has a 1-year low of $2.08 and a 1-year high of $4.34. The firm’s 50 day simple moving average is $3.07 and its 200 day simple moving average is $2.93.

OncoCyte (NASDAQ:OCX) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.36) earnings per share for the quarter. The firm had revenue of $0.10 million during the quarter. OncoCyte had a negative return on equity of 149.88% and a negative net margin of 3,558.46%.

Analyst Ratings Changes

OCX has been the subject of a number of recent research reports. Needham & Company LLC reiterated a “buy” rating and issued a $4.25 price objective on shares of OncoCyte in a research note on Friday, August 9th. StockNews.com began coverage on OncoCyte in a research note on Wednesday. They set a “sell” rating on the stock. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $4.06.

About OncoCyte

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.